uniQure NV
Gesloten
44.57 -1.39
Overzicht
Wijziging aandelenprijs
24u
Min
44.18
Max
45.72
Inkomsten | -28M -81M |
|---|---|
Verkoop | 2.3M 5.8M |
EPS | -1.22 |
Winstmarge | -1,387.759 |
Werknemers | 221 |
EBITDA | -34M -70M |
Volgende Winsten | 9 nov 2026 |
|---|
Marktkapitalisatie | 460M 3.1B |
|---|---|
Vorige openingsprijs | 45.96 |
Vorige sluitingsprijs | 44.57 |
uniQure NV Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
uniQure NV Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.